Page 388 - 20dynamics of cancer

Subject Index

acceleration, see age-specific acceler- 42, 46, 47, 49, 51, 198, 199
ation and DNA repair, 46, 51, 157, 159,
adenoma, 39–42, 45, 46, 48, 244–45, 200, 229
294–95
age-specific acceleration, 17–29, 35, bladder cancer, 35, 247–49, 253,
90, 94–111, 113, 115, 117, 119, 307, 314, 317, 318, 327, 329
120, 123, 124, 130–37, 142, 143, Blaschko, lines of, 305, 306
148–54, 157–61, 195, 202–9, blood
215, 299, 310 cancer, see leukemia
definition, 95 development, see hematopoiesis
log-log acceleration (LLA), defini- supply, see angiogenesis
tion, 95 bone cancer, 23–25, 252, 297
See also age-specific incidence, in- brain cancer, 323, 324, 332
cidence and acceleration curves, breast cancer
plots of Anglian Breast Cancer Study, 228
age-specific incidence BRCA1 and BRCA2, 162, 216–20,
cumulative, 140, 167 227, 228, 232, 241, 242
definition, 94–95, 140 contralateral incidence, 231
late-life plateau and declining epithelial renewal, 264
acceleration, 20, 23, 29, 90, incidence and acceleration, 33, 76,
96–142, 149, 159, 163, 202–9, 90, 216–20, 231–33, 252, 310,
220, 232–33, 299, 310 315, 316
midlife rise in acceleration, 18, mitotic rate, 299
90, 97, 109, 113, 115, 117, 121, polygenic inheritance, 160–64
209, 314
ratio, curves compared by, 92, carcinogens
115, 121, 123–29, 146–64, 216, dose-response, 32, 64, 139–41,
217 166–80, 184, 188–201
sex differences, 32–35, 327–33 Druckrey relation, 33, 90, 139–41,
See also age-specific accelera- 169, 170, 174
tion, incidence and acceleration duration of exposure, 29–32,
curves, plots of 139–41, 166–80, 190–201
aging, 136–39, 202–9, 250, 300 mitogens, 196–98, 269
See also mortality, reliability mutagens, 37, 47, 192–96, 259
models See also laboratory studies, smok-
aneuploidy, see chromosomal insta- ing
bility caretaker genes, 61, 71
angiogenesis, 53, 71 See also DNA repair
animal studies, see laboratory causality, how to study
studies comparative predictions, 48, 65–
APC, see colorectal cancer 68, 70, 76, 87–89, 121, 123–29,
apoptosis 139, 142–64, 166, 190–201,
anti-apoptotic mechanisms, 41, 214–34, 237, 242, 310, 311